Yiran Gan 4/8/25 Yiran Gan 4/8/25 Elevated plasma neurofilament light chain in immune-mediated neurological disorders (IMND) detected by immunomagnetic reduction (IMR) Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Concentration Dependency of Characteristic Times in the Reactions between Protein and Antibody-functionalized Magnetic Nanoparticles via Immunomagnetic Reduction Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Vascular risk factors and astrocytic marker for the glymphatic system activity Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Plasma extracellular vesicles tau and β-amyloid as biomarkers of cognitive dysfunction of Parkinson's disease Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Upregulation of APAF1 and CSF1R in Peripheral Blood Mononuclear Cells of Parkinson’s Disease Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Applications of Immunomagnetic Reduction Technology as a Biosensor in Therapeutic Evaluation of Chinese Herbal Medicine in Tauopathy Alleviation of an AD Drosophila Model Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Continuous Positive Airway Pressure Reduces Plasma Neurochemical Levels in Patients with OSA: A Pilot Study Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia Read More Yiran Gan 4/8/25 Yiran Gan 4/8/25 Associations between blood-based biomarkers of Alzheimer’s disease with cognition in motoric cognitive risk syndrome: A pilot study using plasma Aβ42 and total tau Read More Newer Posts Older Posts
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Elevated plasma neurofilament light chain in immune-mediated neurological disorders (IMND) detected by immunomagnetic reduction (IMR) Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Concentration Dependency of Characteristic Times in the Reactions between Protein and Antibody-functionalized Magnetic Nanoparticles via Immunomagnetic Reduction Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Vascular risk factors and astrocytic marker for the glymphatic system activity Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Plasma extracellular vesicles tau and β-amyloid as biomarkers of cognitive dysfunction of Parkinson's disease Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Upregulation of APAF1 and CSF1R in Peripheral Blood Mononuclear Cells of Parkinson’s Disease Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Applications of Immunomagnetic Reduction Technology as a Biosensor in Therapeutic Evaluation of Chinese Herbal Medicine in Tauopathy Alleviation of an AD Drosophila Model Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Continuous Positive Airway Pressure Reduces Plasma Neurochemical Levels in Patients with OSA: A Pilot Study Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia Read More
Yiran Gan 4/8/25 Yiran Gan 4/8/25 Associations between blood-based biomarkers of Alzheimer’s disease with cognition in motoric cognitive risk syndrome: A pilot study using plasma Aβ42 and total tau Read More
